Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US (healthy volunteers) & Belfast (CF)

    Phase I Study of PTI-808 and triple combination in healthy adults and then in adults with cystic fibrosis , protocol number NCT03500263 PTI-808-01 Proteostasis

    Parts 1 and 2 of this study will take place in healthy volunteers. Part 3 of this study is taking place in adults with cystic fibrosis at multiple care centers across the U.S. It will look at the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      56 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number NCT02564354 PQ-010-002

    This study evaluated the effectiveness of the drug eluforsen (when sprayed in the nose) to improve nasal cell chloride transport. This study was for people with CF who have at least one copy of the F508del CFTR mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number Nivalis N91115-2CF1-05

    This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of F508del CFTR mutation and were also taking lumacaftor/ivacaftor (OrkambiĀ®).

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 85%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SNO1: Study of N6022 in people with cystic fibrosis , protocol number Nivalis N30 N6022-1CF1-04

    This study tested the safety, tolerability of N6022 and its effects on CFTR biomarkers in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      10

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enterel tube feedings , protocol number Alcresta 0000497

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of Relizorb, a new tube feeding in-line digestive enzyme cartridge. This cartridge is used with tube feedings to deliver digestive enzymes.

    • Age:

      4 Years to 82 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 100%

    • Number of Visits:

      4

    • Length of Participation:

      27 days

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Arikace for Nontuberculous Mycobacteria (NTM) , protocol number Insmed 112

    The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.

    • Age:

      12 Years to 75 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation. , protocol number Nivalis N91115-2CF-03

    This study is taking place at multiple care centers across the U.S. It will look at the safety of the drug N91115 as well as how the body processes the drug, in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 2 study of riociguat in adults with CF , protocol number Bayer 63-2521/17020

    This study is taking place at multiple care centers across the U.S. It will look at the safety, tolerability and effectiveness of the oral drug riociguat and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding , protocol number Alcresta 0000498

    This open label study is taking place at multiple care centres across the US. It will look at the safety, tolerability and effectiveness of Relizorb, a new digestive enzyme cartridge for people using enteral tube feedings.

    • Age:

      4 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 100%

    • Number of Visits:

      5

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Displaying results 101-110 (of 168)
     |<  <  7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16  >  >|